Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 9:09 PM
Ignite Modification Date: 2025-12-24 @ 9:09 PM
NCT ID: NCT01956604
Eligibility Criteria: Inclusion Criteria: * Patient \> 65 years old admitted to the Medical department * Delirium or subsyndromal delirium diagnosed within the last 48 hours * Signed informed consent from patient or relatives * Expected cooperation of the patients for the treatment and follow up Exclusion Criteria: * Symptomatic bradycardia, bradycardia due to sick-sinus-syndrome, second- or third- degree AV-block (not treated With pacemaker) or any other reason causing HR \<50 bpm at time of inclusion * Symptomatic hypotension or orthostatic hypotension, or a systolic BP \<120 at the time of inclusion * Ischemic stroke within the last 3 months or critical peripheral ischemia * Acute coronary syndrome, unstable or severe coronary heart disease (symptoms at minimal physical activity; NYHA 3 and 4) and moderate to severe heart failure (NYHA 3 and 4). * A diagnosis of polyneuropathy or pheochromocytoma * Renal insufficiency (estimated GFR\<30 ml/min according to the MDRD formula). * Body weight \< 45 kg. * Considered as moribund on admission. * Not able to take oral medications * Current use of tricyclic antidepressants, monoamine reuptake inhibitors or ciclosporin * Previously included in this study * Adverse reactions to clonidine or excipients (lactose, saccharose) * Not speaking or reading Norwegian * Any other condition as evaluated by the treating physician * Admitted to the ICU
Healthy Volunteers: False
Sex: ALL
Minimum Age: 65 Years
Study: NCT01956604
Study Brief:
Protocol Section: NCT01956604